Used primarily in pharmaceutical research as a key intermediate in the synthesis of targeted protein degraders, particularly cereblon (CRBN)-based PROTACs (proteolysis-targeting chimeras). Its structure enables conjugation between an E3 ligase binder and a target protein ligand, facilitating the ubiquitination and subsequent degradation of disease-related proteins. It is especially valuable in oncology and immunomodulatory drug development due to its ability to engage cereblon effectively. Also explored in the design of molecular glues and bifunctional degraders for treating cancers such as multiple myeloma and other hematological malignancies.